Sandoz Starts Generic Tirzepatide Race With FDA Filing Acceptance
Developed in-house by combining expertise in small molecules, devices, and biosimilars, Sandoz intends for its tirzepatide to be the first generic rival to Mounjaro/Zepbound autoinjectors.
Generics Bulletin - June 29, 2026

India Proposes Faster Medical Device Manufacturing License Timelines
India's health ministry has proposed cutting manufacturing license timelines for medical devices across risk classes, targeting greater regulatory efficiency — but industry body AiMeD has flagged a puzzling anomaly.
Medtech Insight - June 29, 2026

Roche Bets Flexible Economics Can Loosen The Batching Trap That Defines NGS
Roche pitches AXELIOS 1's reusable-sensor economics as the cure for the NGS "batching penalty," backed by early collaborator data and a near-term NICU use case, as it starts on the path from research-use to clinical diagnostics.
Medtech Insight - June 29, 2026

Pipeline Watch: Japan Dominates Thirty-Four Approvals Plus Seven Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - June 29, 2026

Biocon Grows Malaysian Insulin Presence With A $54m Government Tender Deal
Three multi-year insulin product agreements with Biocon will push Malaysia’s ambition for healthcare self-reliance and domestic manufacturing security.
Generics Bulletin - June 29, 2026

Top Medtechs’ Annual Average Growth Hits 8.5%
A handful of ranking changes among medtech’s topmost global tier in an industry showing healthy growth were reflected in In Vivo’s US dollar-rankings for calendar 2025.
In Vivo - June 29, 2026

CHMP Nods Deepen Crowded Denosumab, Pegfilgrastim Biosimilar Fields
The EMA’s CHMP has backed Ascend’s self-titled denosumab and Qilu’s Nylaspeg, adding further competition to already crowded European denosumab and pegfilgrastim biosimilar markets.
Generics Bulletin - June 29, 2026

Norwich Ruling Strengthens Bausch’s Grip On Xifaxan
Norwich Pharmaceuticals has lost its administrative-law challenge to the FDA over its skinny-label generic of Bausch Health’s Xifaxan, with the D.C. Circuit affirming that the agency was right to withhold final approval until Salix’s hepatic-encephalopathy patents expire in 2029.
Generics Bulletin - June 29, 2026

Getting The EU MDR ‘Mostly Right’ Is A Juggling Act – The German Industry View
Germany’s BVMed industry association head of regulation Christina Ziegenberg laid out the possible route ahead for the EU co-legislators’ negotiations over amendments to the MDR and IVDR.
Medtech Insight - June 29, 2026

‘Stop Talking And Do’: The Team Player Taking A Proactive Oversight Approach At Link Biologics
Reuben Dawkins, CEO and co-founder of Link Biologics, knows the catalysts for innovation. The In Vivo Rising Leader discusses the gap between scientific discovery and commercialization, highlighting the potential of TSG-6, a naturally occurring protein just waiting to be commercialized.
In Vivo - June 29, 2026

Roche Launches AXELIOS 1 Sequencer At $750,000, Targeting Illumina’s Market
Roche launches AXELIOS 1, a $750,000 sequencer offering $150 genomes and a sub-four-hour whole-genome turnaround under optimized conditions. With middle-ground read lengths and reusable sensor economics, will this broaden access or just add to an already crowded market.
Medtech Insight - June 29, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: China deal controls a hot BIO topic; pharma eyes $2 trillion in sales; Apogee helps AbbVie achieve vision; Sangamo files for bankruptcy; and a review of Weber’s time at Takeda.
Scrip - June 29, 2026